Home » Topics » BioWorld Science

BioWorld Science
RSS

Pfizer enrolling patients in phase III trial of glasdegib for the treatment of AML

April 20, 2018

AzurRx BioPharma's AZ-1103 safe and biologically active in preclinical model

April 20, 2018

Qu Biologics initiates phase II trial for QBECO in Crohn's disease

April 19, 2018

FDA grants rare pediatric disease designation to sevuparin for children with sickle cell disease

April 19, 2018

Boehringer Ingelheim patents hSTING agonists

April 19, 2018

New EHMT1 and/or EHMT2 inhibitors presented by Epizyme

April 19, 2018

Novel compound targets multiple immune checkpoint elements

April 19, 2018

Pear Therapeutics and Sandoz sign agreement for prescription digital therapeutics

April 19, 2018

Institut Pasteur Korea divulges new compounds for influenza

April 19, 2018

FDA grants priority review to sBLA for Opdivo in previously treated SCLC

April 19, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...